Skip to main content
Top
Published in: Virology Journal 1/2017

Open Access 01-12-2017 | Research

HPV11 E6 mutation by overexpression of APOBEC3A and effects of interferon-ω on APOBEC3s and HPV11 E6 expression in HPV11.HaCaT cells

Authors: Yongfang Wang, Xinyu Li, Shasha Song, Yang Sun, Jiafen Zhang, Changming Yu, Wei Chen

Published in: Virology Journal | Issue 1/2017

Login to get access

Abstract

Background

Condyloma acuminatum, infected by low-risk human papillomaviruses (e.g., HPV6 and HPV11), is one of the most widespread sexually transmitted diseases. Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 proteins (APOBEC3s, A3s) are cellular cytidine deaminases acting as antiviral factors through hypermutation of viral genome. However, it remains unknown whether A3s results in HPV11 gene mutations and interferon-ω (IFN-ω) exhibits antiviral activities through the A3s system. Here we investigated whether enhanced APOBEC3A (A3A) resulted in the E6 gene mutations and explore the effects of recombinant human interferon-ω (rhIFN-ω) on A3s/E6 expression in HaCaT keratinocytes containing the genome of HPV 11 (HPV11.HaCaT cells).

Methods

A3A-overexpressed HPV11.HaCaT (A3A-HPV11.HaCaT) cells were established by lentiviral infection and verified by immunofluorescence and western-blotting. Cell cycle, E6 gene mutations, APOBEC3s/E6 gene expression and subcellular localization were detected by FACS, 3D-PCR and sequencing, qRT-PCR and immunofluorescence respectively.

Results

The results suggested that A3A-HPV11.HaCaT cells were successfully established. Enhanced A3A induced S-phase arrest, G > A/C > T mutations and obvious reduction of E6 mRNA expression. A3A/A3B mRNA expression was up-regulated at 6 h and 12 h and obvious A3A staining existed throughout HPV11.HaCaT cells after rhIFN-ω treatment. RhIFN-ω could also inhibit mRNA expression of HPV11 E6 significantly.

Conclusions

Enhanced A3A repressed HPV11 E6 expression through gene hypermutation, and rhIFN-ω might be an effective agent against HPV11 infection by up-regulation of A3A.
Literature
1.
go back to reference Mirghani H, Amen F, Tao Y, Deutsch E, Levy A. Increased radiosensitivity of HPV-positive head and neck cancers: molecular basis and therapeutic perspectives. Cancer Treat Rev. 2015;41:844–52.CrossRefPubMed Mirghani H, Amen F, Tao Y, Deutsch E, Levy A. Increased radiosensitivity of HPV-positive head and neck cancers: molecular basis and therapeutic perspectives. Cancer Treat Rev. 2015;41:844–52.CrossRefPubMed
6.
go back to reference Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res. 2017;231:21–33.CrossRefPubMed Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res. 2017;231:21–33.CrossRefPubMed
7.
go back to reference Bennetts LE, Wagner M, Giuliano AR, Palefsky JM, Steben M, Weiss TW. Associations of Anogenital low-risk human Papillomavirus infection with cancer and acquisition of HIV. Sex Transm Dis. 2015;42:541–4.CrossRefPubMed Bennetts LE, Wagner M, Giuliano AR, Palefsky JM, Steben M, Weiss TW. Associations of Anogenital low-risk human Papillomavirus infection with cancer and acquisition of HIV. Sex Transm Dis. 2015;42:541–4.CrossRefPubMed
8.
go back to reference Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9:679–91.PubMedPubMedCentral Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9:679–91.PubMedPubMedCentral
10.
go back to reference Desimmie BA, Burdick RC, Izumi T, Doi H, Shao W, Alvord WG, Sato K, Koyanagi Y, Jones S, Wilson E, et al. APOBEC3 proteins can copackage and comutate HIV-1 genomes. Nucleic Acids Res. 2016;44:7848–65.CrossRefPubMedPubMedCentral Desimmie BA, Burdick RC, Izumi T, Doi H, Shao W, Alvord WG, Sato K, Koyanagi Y, Jones S, Wilson E, et al. APOBEC3 proteins can copackage and comutate HIV-1 genomes. Nucleic Acids Res. 2016;44:7848–65.CrossRefPubMedPubMedCentral
11.
go back to reference Janahi EM, McGarvey MJ. The inhibition of hepatitis B virus by APOBEC cytidine deaminases. J Viral Hepat. 2013;20:821–8.CrossRefPubMed Janahi EM, McGarvey MJ. The inhibition of hepatitis B virus by APOBEC cytidine deaminases. J Viral Hepat. 2013;20:821–8.CrossRefPubMed
12.
go back to reference Vartanian JP, Guetard D, Henry M, Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science. 2008;320:230–3.CrossRefPubMed Vartanian JP, Guetard D, Henry M, Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science. 2008;320:230–3.CrossRefPubMed
14.
go back to reference Middlebrooks CD, Banday AR, Matsuda K, Udquim KI, Onabajo OO, Paquin A, Figueroa JD, Zhu B, Koutros S, Kubo M, et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet. 2016;48:1330–8.CrossRefPubMed Middlebrooks CD, Banday AR, Matsuda K, Udquim KI, Onabajo OO, Paquin A, Figueroa JD, Zhu B, Koutros S, Kubo M, et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet. 2016;48:1330–8.CrossRefPubMed
15.
go back to reference Kondo S, Wakae K, Wakisaka N, Nakanishi Y, Ishikawa K, Komori T, Moriyama-Kita M, Endo K, Murono S, Wang Z, et al. APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers. Oncogene. 2017;36:1687–97.CrossRefPubMed Kondo S, Wakae K, Wakisaka N, Nakanishi Y, Ishikawa K, Komori T, Moriyama-Kita M, Endo K, Murono S, Wang Z, et al. APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers. Oncogene. 2017;36:1687–97.CrossRefPubMed
16.
go back to reference Wang Z, Wakae K, Kitamura K, Aoyama S, Liu G, Koura M, Monjurul AM, Kukimoto I, Muramatsu M. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J Virol. 2014;88:1308–17.CrossRefPubMedPubMedCentral Wang Z, Wakae K, Kitamura K, Aoyama S, Liu G, Koura M, Monjurul AM, Kukimoto I, Muramatsu M. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J Virol. 2014;88:1308–17.CrossRefPubMedPubMedCentral
17.
go back to reference Kukimoto I, Mori S, Aoyama S, Wakae K, Muramatsu M, Kondo K. Hypermutation in the E2 gene of human papillomavirus type 16 in cervical intraepithelial neoplasia. J Med Virol. 2015;87:1754–60.CrossRefPubMed Kukimoto I, Mori S, Aoyama S, Wakae K, Muramatsu M, Kondo K. Hypermutation in the E2 gene of human papillomavirus type 16 in cervical intraepithelial neoplasia. J Med Virol. 2015;87:1754–60.CrossRefPubMed
18.
go back to reference Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550–60.CrossRefPubMed Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550–60.CrossRefPubMed
19.
go back to reference Marullo R, Werner E, Zhang H, Chen GZ, Shin DM, Doetsch PW. HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. Carcinogenesis. 2015;36:1397–406.CrossRefPubMedPubMedCentral Marullo R, Werner E, Zhang H, Chen GZ, Shin DM, Doetsch PW. HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. Carcinogenesis. 2015;36:1397–406.CrossRefPubMedPubMedCentral
20.
go back to reference Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Vande PS, Podjarny A, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016;529:541–5.CrossRefPubMedPubMedCentral Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Vande PS, Podjarny A, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016;529:541–5.CrossRefPubMedPubMedCentral
21.
go back to reference Wallace NA, Galloway DA. Novel functions of the human Papillomavirus E6 Oncoproteins. Annu Rev Virol. 2015;2:403–23.CrossRefPubMed Wallace NA, Galloway DA. Novel functions of the human Papillomavirus E6 Oncoproteins. Annu Rev Virol. 2015;2:403–23.CrossRefPubMed
22.
go back to reference Danielewski JA, Garland SM, McCloskey J, Hillman RJ, Tabrizi SN. Human papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial samples from Australia. PLoS One. 2013;8:e63892.CrossRefPubMedPubMedCentral Danielewski JA, Garland SM, McCloskey J, Hillman RJ, Tabrizi SN. Human papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial samples from Australia. PLoS One. 2013;8:e63892.CrossRefPubMedPubMedCentral
23.
go back to reference Wang Y, Li X, Song S, Sun Y. Expression of APOBEC3s in HaCaT keratinocytes containing the genome of human papillomavirus type 11 and regulatory function of interferon-alpha. Chin. J Dermatol. 2016;49(2):88–92. Wang Y, Li X, Song S, Sun Y. Expression of APOBEC3s in HaCaT keratinocytes containing the genome of human papillomavirus type 11 and regulatory function of interferon-alpha. Chin. J Dermatol. 2016;49(2):88–92.
24.
go back to reference Bracci L, Sistigu A, Proietti E, Moschella F. The added value of type I interferons to cytotoxic treatments of cancer. Cytokine Growth Factor Rev. 2017;36:89–97.CrossRefPubMed Bracci L, Sistigu A, Proietti E, Moschella F. The added value of type I interferons to cytotoxic treatments of cancer. Cytokine Growth Factor Rev. 2017;36:89–97.CrossRefPubMed
25.
go back to reference Sun Y, Li X, Song S, Wang Y, Gu H. Integrity of a HPV11 infection cell model and identification of (−)-Epigallocatechin-3-gallate as a potential HPV11 inhibitor. Oncotarget. 2016;7:37092–102.CrossRefPubMedPubMedCentral Sun Y, Li X, Song S, Wang Y, Gu H. Integrity of a HPV11 infection cell model and identification of (−)-Epigallocatechin-3-gallate as a potential HPV11 inhibitor. Oncotarget. 2016;7:37092–102.CrossRefPubMedPubMedCentral
26.
go back to reference Buckwold VE, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells. Basic Clin Pharmacol Toxicol. 2006;99:62–70.CrossRefPubMed Buckwold VE, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells. Basic Clin Pharmacol Toxicol. 2006;99:62–70.CrossRefPubMed
27.
go back to reference Skorvanova L, Svancarova P, Svetlikova D, Betakova T. Protective efficacy of IFN-omega AND IFN-lambdas against influenza viruses in induced A549 cells. Acta Virol. 2015;59:413–7.CrossRefPubMed Skorvanova L, Svancarova P, Svetlikova D, Betakova T. Protective efficacy of IFN-omega AND IFN-lambdas against influenza viruses in induced A549 cells. Acta Virol. 2015;59:413–7.CrossRefPubMed
28.
go back to reference Hagelstein J, Kist A, Stremmel W, Galle PR. Antiviral potential of interferon-omega on hepatitis B virus replication in human hepatoma cells. Arzneimittelforschung. 1998;48:343–7.PubMed Hagelstein J, Kist A, Stremmel W, Galle PR. Antiviral potential of interferon-omega on hepatitis B virus replication in human hepatoma cells. Arzneimittelforschung. 1998;48:343–7.PubMed
29.
go back to reference Buckwold VE, Wei J, Huang Z, Huang C, Nalca A, Wells J, Russell J, Collins B, Ptak R, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antivir Res. 2007;73:118–25.CrossRefPubMed Buckwold VE, Wei J, Huang Z, Huang C, Nalca A, Wells J, Russell J, Collins B, Ptak R, Lang W, Scribner C, Blanchett D, Alessi T, Langecker P. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antivir Res. 2007;73:118–25.CrossRefPubMed
30.
go back to reference Wang Y, Li X, Song S, Wu J. Development of basal-like HaCaT Keratinocytes containing the genome of human Papillomavirus (HPV) type 11 for screening of anti-HPV effects. J Biomol Screen. 2014;19:1154–63.CrossRefPubMed Wang Y, Li X, Song S, Wu J. Development of basal-like HaCaT Keratinocytes containing the genome of human Papillomavirus (HPV) type 11 for screening of anti-HPV effects. J Biomol Screen. 2014;19:1154–63.CrossRefPubMed
31.
go back to reference Warren CJ, Xu T, Guo K, Griffin LM, Westrich JA, Lee D, Lambert PF, Santiago ML, Pyeon D. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol. 2015;89:688–702.CrossRefPubMed Warren CJ, Xu T, Guo K, Griffin LM, Westrich JA, Lee D, Lambert PF, Santiago ML, Pyeon D. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol. 2015;89:688–702.CrossRefPubMed
32.
go back to reference Lackey L, Law EK, Brown WL, Harris RS. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle. 2013;12:762–72.CrossRefPubMedPubMedCentral Lackey L, Law EK, Brown WL, Harris RS. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle. 2013;12:762–72.CrossRefPubMedPubMedCentral
33.
go back to reference Lyman RC, Wilson ML, Herrington CS. Cell-cycle control protein expression is disrupted in anogenital condylomata infected with low-risk human papillomavirus types. J Low Genit Tract Dis. 2008;12:224–31.CrossRefPubMed Lyman RC, Wilson ML, Herrington CS. Cell-cycle control protein expression is disrupted in anogenital condylomata infected with low-risk human papillomavirus types. J Low Genit Tract Dis. 2008;12:224–31.CrossRefPubMed
34.
go back to reference Reinson T, Henno L, Toots M, Ustav MJ, Ustav M. The cell cycle timing of human Papillomavirus DNA replication. PLoS One. 2015;10:e131675.CrossRef Reinson T, Henno L, Toots M, Ustav MJ, Ustav M. The cell cycle timing of human Papillomavirus DNA replication. PLoS One. 2015;10:e131675.CrossRef
35.
go back to reference Fuertes MB, Woo SR, Burnett B, YX F, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013;34:67–73.CrossRefPubMed Fuertes MB, Woo SR, Burnett B, YX F, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 2013;34:67–73.CrossRefPubMed
36.
go back to reference He X, Korytař T, Schatz J, Freuling CM, Müller T, Köllner B. Anti-lyssaviral activity of interferons κ and ω from the serotine bat, Eptesicus Serotinus. J Virol. 2014;88:5444–54.CrossRefPubMedPubMedCentral He X, Korytař T, Schatz J, Freuling CM, Müller T, Köllner B. Anti-lyssaviral activity of interferons κ and ω from the serotine bat, Eptesicus Serotinus. J Virol. 2014;88:5444–54.CrossRefPubMedPubMedCentral
Metadata
Title
HPV11 E6 mutation by overexpression of APOBEC3A and effects of interferon-ω on APOBEC3s and HPV11 E6 expression in HPV11.HaCaT cells
Authors
Yongfang Wang
Xinyu Li
Shasha Song
Yang Sun
Jiafen Zhang
Changming Yu
Wei Chen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2017
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-017-0878-2

Other articles of this Issue 1/2017

Virology Journal 1/2017 Go to the issue